The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...

Corvus Pharmaceuticals' Soquelitinib shows promise for PTCL & more, but financial risks and competition raise concerns. Learn more about CRVS stock here.

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

Seagen was a pioneer in the development of ADC drugs, and has successfully brought two to market – Adcetris (brentuximab vedotin) for various type of lymphoma and Padcev (enfortumab vedotin ...

Seagen has a long history in ADC development, claiming FDA approval for Adcetris (brentuximab vedotin) as a treatment for classical Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL ...

June 20, 2024 — Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to ...

NEW YORK, February 24, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at ...

Marlise R. Luskin, MD, MSCE, a member of the Adult Leukemia Program at Dana-Farber Cancer Institute, associate program director of the Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship ...

First-in-class novel, oral KAT2A/B degrader AUTX-703 was granted FDA fast track designation to treat relapsed/refractory acute myelogenous leukemia (AML). 1 Previously, on February 4, 2025, the FDA ...

RZ-001, an RNA substitution enzyme-based cancer gene therapy, has been granted FDA fast track designation for hepatocellular carcinoma (HCC), per a press release from Rznomics Inc. 1 This regulatory ...